Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro - PubMed (original) (raw)
Comparative Study
. 1995 May;95(5):2004-11.
doi: 10.1172/JCI117885.
Affiliations
- PMID: 7738167
- PMCID: PMC295778
- DOI: 10.1172/JCI117885
Comparative Study
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro
M Riegler et al. J Clin Invest. 1995 May.
Abstract
Toxin A but not toxin B, appears to mediate intestinal damage in animal models of Clostridium difficile enteritis. The purpose of this study was to investigate the electrophysiologic and morphologic effects of purified C. difficile toxins A and B on human colonic mucosa in Ussing chambers. Luminal exposure of tissues to 16-65 nM of toxin A and 0.2-29 nM of toxin B for 5 h caused dose-dependent epithelial damage. Potential difference, short-circuit current and resistance decreased by 76, 58, and 46%, respectively, with 32 nM of toxin A and by 76, 55, and 47%, respectively, with 3 nM of toxin B, when compared with baseline (P < 0.05). 3 nM of toxin A did not cause electrophysiologic changes. Permeability to [3H]mannitol increased 16-fold after exposure to 32 nM of toxin A and to 3 nM of toxin B when compared with controls (P < 0.05). Light and scanning electron microscopy after exposure to either toxin revealed patchy damage and exfoliation of superficial epithelial cells, while crypt epithelium remained intact. Fluorescent microscopy of phalloidin-stained sections showed that both toxins caused disruption and condensation of cellular F-actin. Our results demonstrate that the human colon is approximately 10 times more sensitive to the damaging effects of toxin B than toxin A, suggesting that toxin B may be more important than toxin A in the pathogenesis of C. difficile colitis in man.
Similar articles
- Epidermal growth factor attenuates Clostridium difficile toxin A- and B-induced damage of human colonic mucosa.
Riegler M, Sedivy R, Sogukoglu T, Castagliuolo I, Pothoulakis C, Cosentini E, Bischof G, Hamilton G, Teleky B, Feil W, Lamont JT, Wenzl E. Riegler M, et al. Am J Physiol. 1997 Nov;273(5):G1014-22. doi: 10.1152/ajpgi.1997.273.5.G1014. Am J Physiol. 1997. PMID: 9374697 - Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Castagliuolo I, et al. Infect Immun. 1999 Jan;67(1):302-7. doi: 10.1128/IAI.67.1.302-307.1999. Infect Immun. 1999. PMID: 9864230 Free PMC article. - C. difficile toxin A increases intestinal permeability and induces Cl- secretion.
Moore R, Pothoulakis C, LaMont JT, Carlson S, Madara JL. Moore R, et al. Am J Physiol. 1990 Aug;259(2 Pt 1):G165-72. doi: 10.1152/ajpgi.1990.259.2.G165. Am J Physiol. 1990. PMID: 2116728 - Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.
Lamont JT. Lamont JT. Trans Am Clin Climatol Assoc. 2002;113:167-80; discussion 180-1. Trans Am Clin Climatol Assoc. 2002. PMID: 12053708 Free PMC article. Review. - The role of toxin A and toxin B in the virulence of Clostridium difficile.
Carter GP, Rood JI, Lyras D. Carter GP, et al. Trends Microbiol. 2012 Jan;20(1):21-9. doi: 10.1016/j.tim.2011.11.003. Epub 2011 Dec 7. Trends Microbiol. 2012. PMID: 22154163 Review.
Cited by
- Clostridioides difficile Toxins: Host Cell Interactions and Their Role in Disease Pathogenesis.
Alam MZ, Madan R. Alam MZ, et al. Toxins (Basel). 2024 May 24;16(6):241. doi: 10.3390/toxins16060241. Toxins (Basel). 2024. PMID: 38922136 Free PMC article. Review. - Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.
Norman KM, Lang GA, Shadid TM, Honold ST, Reel JM, Cox MA, Ballard JD, Lang ML. Norman KM, et al. Cell Rep. 2024 May 28;43(5):114245. doi: 10.1016/j.celrep.2024.114245. Epub 2024 May 17. Cell Rep. 2024. PMID: 38761377 Free PMC article. - Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies.
Sinnathamby ES, Mason JW, Flanagan CJ, Pearl NZ, Burroughs CR, De Witt AJ, Wenger DM, Klapper VG, Ahmadzadeh S, Varrassi G, Shekoohi S, Kaye AD. Sinnathamby ES, et al. Cureus. 2023 Dec 27;15(12):e51167. doi: 10.7759/cureus.51167. eCollection 2023 Dec. Cureus. 2023. PMID: 38283489 Free PMC article. Review. - Characterization of community-acquired Clostridioides difficile strains in Israel, 2020-2022.
Schwartz O, Rohana H, Azrad M, Shor A, Rainy N, Maor Y, Nesher L, Sagi O, Ken-Dror S, Kechker P, Peretz A. Schwartz O, et al. Front Microbiol. 2023 Dec 19;14:1323257. doi: 10.3389/fmicb.2023.1323257. eCollection 2023. Front Microbiol. 2023. PMID: 38169783 Free PMC article. - Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection.
Rubio-Mendoza D, Martínez-Meléndez A, Maldonado-Garza HJ, Córdova-Fletes C, Garza-González E. Rubio-Mendoza D, et al. Microorganisms. 2023 Oct 10;11(10):2525. doi: 10.3390/microorganisms11102525. Microorganisms. 2023. PMID: 37894183 Free PMC article. Review.
References
- J Infect Dis. 1977 Nov;136(5):701-5 - PubMed
- Gastroenterology. 1992 Feb;102(2):416-23 - PubMed
- Gastroenterology. 1978 Nov;75(5):778-82 - PubMed
- Gut. 1980 Jun;21(6):493-9 - PubMed
- Infect Immun. 1982 Mar;35(3):1032-40 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources